These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 10160079)

  • 21. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibiotic therapy 1985: what are the challenges?
    Cohen MS
    Hosp Formul; 1985 Dec; 20(12):1247-8. PubMed ID: 10311346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Macrolides: present and future. An appraisal of in-vitro activity and pharmacokinetic behavior.
    Furneri PM; Nicoletti G
    J Chemother; 1991 Jan; 3 Suppl 1():24-7. PubMed ID: 12041776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.
    Lipsy RJ
    Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactions.
    Rapp RP
    Ann Pharmacother; 1998; 32(7-8):785-93. PubMed ID: 9681095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review of macrolides and ketolides: focus on respiratory tract infections.
    Zhanel GG; Dueck M; Hoban DJ; Vercaigne LM; Embil JM; Gin AS; Karlowsky JA
    Drugs; 2001; 61(4):443-98. PubMed ID: 11324679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of new antimicrobials for the hospital formulary. Policies restricting antibiotic use in hospitals.
    Pujol M; Delgado O; Puigventós F; Corzo JE; Cercenado E; Martínez JA
    Enferm Infecc Microbiol Clin; 2013 Sep; 31 Suppl 4():45-50. PubMed ID: 24129289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.
    Schentag JJ; Birmingham MC; Paladino JA; Carr JR; Hyatt JM; Forrest A; Zimmer GS; Adelman MH; Cumbo TJ
    Semin Respir Infect; 1997 Dec; 12(4):278-93. PubMed ID: 9436955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Choosing the right macrolide antibiotic. A guide to selection.
    Charles L; Segreti J
    Drugs; 1997 Mar; 53(3):349-57. PubMed ID: 9074839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
    Feldman C
    J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia.
    Bhavnani SM; Ambrose PG
    Diagn Microbiol Infect Dis; 2008 Jan; 60(1):59-64. PubMed ID: 17889491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Macrolide antibiotics.
    Gordon RC
    Indian J Pediatr; 1998; 65(1):1-9. PubMed ID: 10771940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Macrolones Are a Novel Class of Macrolide Antibiotics Active against Key Resistant Respiratory Pathogens In Vitro and In Vivo.
    Čipčić Paljetak H; Verbanac D; Padovan J; Dominis-Kramarić M; Kelnerić Ž; Perić M; Banjanac M; Ergović G; Simon N; Broskey J; Holmes DJ; Eraković Haber V
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5337-48. PubMed ID: 27353268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Macrolide antibiotics.
    Pallasch TJ
    Dent Today; 1997 Nov; 16(11):72, 74-5, 78-9. PubMed ID: 9560736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial formulary management: a consultant's perspective.
    Holzman MS
    Pharmacotherapy; 1991; 11(1 ( Pt 2)):14S-18S. PubMed ID: 2011568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Short course antibiotherapies in community-acquired pneumonia].
    Bulbul Y; Ozlu T
    Tuberk Toraks; 2008; 56(3):344-52. PubMed ID: 18932039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Azithromycin: the first azalide antibiotic.
    Ballow CH; Amsden GW
    Ann Pharmacother; 1992 Oct; 26(10):1253-61. PubMed ID: 1330097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Formulary management of ACE inhibitors.
    Gerbrandt KR; Yedinak KC
    Pharmacoeconomics; 1996 Dec; 10(6):594-613. PubMed ID: 10164060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic decision-making: a model for formulary evaluation.
    Sesin GP
    Drug Intell Clin Pharm; 1986; 20(7-8):581-3. PubMed ID: 3743414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug formulary review process for sargramostim and filgrastim: focus on analysis of adverse drug reactions.
    Kellihan MJ
    Clin Ther; 1993; 15(5):927-37. PubMed ID: 7505717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.